TargetMol

Thalidomide-propargyl

Product Code:
 
TAR-T18831
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T18831-2mg2mg£102.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T18831-5mg5mg£122.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T18831-10mg10mg£158.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T18831-25mg25mg£230.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T18831-50mg50mg£345.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T18831-100mg100mg£482.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Thalidomide-propargyl is the Thalidomide-based Cereblon ligand used in the recruitment of Cereblon. Thalidomide-propargyl can be connected to the ligand for protein by a linker to form the IMiD containing PROTACs.
CAS:
2098487-39-7
Formula:
C16H12N2O5
Molecular Weight:
312.281
Pathway:
Others|PROTAC
Purity:
0.9514
SMILES:
O=C1N(C2CCC(=O)NC2=O)C(=O)c2c1cccc2OCC#C
Target:
Others|Ligand for E3 Ligase

References

1. Wurz RP, et al. A "Click Chemistry Platform" for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation. J Med Chem. 2018 Jan 25;61(2):453-461.